• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

瑞格列净在2型糖尿病患者中的安全性和有效性：一项系统评价和荟萃分析。

Safety and Efficacy of Remogliflozin in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

作者信息

Tewari Jay, Qidwai Khalid Ahmad, Rana Anadika, Tewari Ajoy, Tewari Vineeta, Maheshwari Anuj

机构信息

Internal Medicine, King George's Medical University, Lucknow, IND.

Internal Medicine, Aasra Hospital, Lucknow, IND.

出版信息

Cureus. 2024 Aug 4;16(8):e66145. doi: 10.7759/cureus.66145. eCollection 2024 Aug.

DOI:10.7759/cureus.66145
PMID:39233944
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11372186/
Abstract

Remogliflozin is a novel SGLT-2 inhibitor used for the management of Type 2 Diabetes Mellitus (T2DM). Since its introduction medical literature is scarce on its quantitative effects. We performed this meta-analysis to ascertain its safety and efficacy in the treatment of T2DM. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the Cochrane Handbook, six studies involving 1,605 participants were analyzed. Our analysis found comparable reductions in glycated hemoglobin (HbA1c) by remogliflozin in comparison to the comparators. It was found to be inferior to other anti-diabetic drugs in decreasing fasting plasma glucose and post-prandial glucose. A significant reduction was obtained in body weight and a significant increase was also found in high-density lipoprotein cholesterol (HDL-C) levels. Remogliflozin did not significantly increase the risk for total adverse events, severe adverse events, or hypoglycemic episodes. The results were accompanied by high heterogeneity, which necessitates conducting high-quality randomized control trials for more robust evidence synthesis. Overall Remogliflozin can be considered a safe drug with beneficial effects on body weight and HDL-C levels for the treatment of people with T2DM.

摘要

瑞格列净是一种用于治疗2型糖尿病（T2DM）的新型钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂。自其问世以来，关于其定量效应的医学文献较少。我们进行了这项荟萃分析，以确定其在治疗T2DM中的安全性和有效性。按照系统评价和荟萃分析的首选报告项目（PRISMA）指南以及Cochrane手册，对六项涉及1605名参与者的研究进行了分析。我们的分析发现，与对照药物相比，瑞格列净使糖化血红蛋白（HbA1c）有类似程度的降低。结果发现，在降低空腹血糖和餐后血糖方面，它不如其他抗糖尿病药物。体重显著降低，高密度脂蛋白胆固醇（HDL-C）水平也显著升高。瑞格列净并未显著增加总体不良事件、严重不良事件或低血糖发作的风险。结果存在高度异质性，这需要开展高质量的随机对照试验以进行更有力的证据综合分析。总体而言，瑞格列净可被视为一种安全的药物，对T2DM患者的体重和HDL-C水平具有有益作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/faef05c5f0ae/cureus-0016-00000066145-i15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/54125b379275/cureus-0016-00000066145-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/d347677fa344/cureus-0016-00000066145-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/a070597d0ce4/cureus-0016-00000066145-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/3efc2ac77cc5/cureus-0016-00000066145-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/748621eb42df/cureus-0016-00000066145-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/e273608fe97e/cureus-0016-00000066145-i06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/328ee522231f/cureus-0016-00000066145-i07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/dfad2ddee4b0/cureus-0016-00000066145-i08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/fd8c8a513664/cureus-0016-00000066145-i09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/33753715854a/cureus-0016-00000066145-i10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/3afb124342fd/cureus-0016-00000066145-i11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/b1b20b72e2de/cureus-0016-00000066145-i12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/ea9f3d2e73ed/cureus-0016-00000066145-i13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/5ebc6b2bcf0f/cureus-0016-00000066145-i14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/faef05c5f0ae/cureus-0016-00000066145-i15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/54125b379275/cureus-0016-00000066145-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/d347677fa344/cureus-0016-00000066145-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/a070597d0ce4/cureus-0016-00000066145-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/3efc2ac77cc5/cureus-0016-00000066145-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/748621eb42df/cureus-0016-00000066145-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/e273608fe97e/cureus-0016-00000066145-i06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/328ee522231f/cureus-0016-00000066145-i07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/dfad2ddee4b0/cureus-0016-00000066145-i08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/fd8c8a513664/cureus-0016-00000066145-i09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/33753715854a/cureus-0016-00000066145-i10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/3afb124342fd/cureus-0016-00000066145-i11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/b1b20b72e2de/cureus-0016-00000066145-i12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/ea9f3d2e73ed/cureus-0016-00000066145-i13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/5ebc6b2bcf0f/cureus-0016-00000066145-i14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c504/11372186/faef05c5f0ae/cureus-0016-00000066145-i15.jpg

相似文献

1
Safety and Efficacy of Remogliflozin in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.瑞格列净在2型糖尿病患者中的安全性和有效性：一项系统评价和荟萃分析。
Cureus. 2024 Aug 4;16(8):e66145. doi: 10.7759/cureus.66145. eCollection 2024 Aug.
2
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
3
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.二肽基肽酶（DPP）-4抑制剂和胰高血糖素样肽（GLP）-1类似物用于预防或延缓2型糖尿病高危人群发生2型糖尿病及其相关并发症。
Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
5
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
6
Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.胰岛素促泌剂用于预防或延缓2型糖尿病高危人群发生2型糖尿病及其相关并发症。
Cochrane Database Syst Rev. 2016 Oct 17;10(10):CD012151. doi: 10.1002/14651858.CD012151.pub2.
7
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂（GLP-1 RAs）减肥效果的网状Meta分析的数量、质量及结果：一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
9
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.抗血管内皮生长因子治疗糖尿病性黄斑水肿：一项网状Meta分析。
Cochrane Database Syst Rev. 2017 Jun 22;6(6):CD007419. doi: 10.1002/14651858.CD007419.pub5.
10
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.抗抑郁药治疗成人慢性疼痛的疼痛管理：一项网络荟萃分析。
Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948.

引用本文的文献

1
SGLT2 Inhibitors: From Structure-Effect Relationship to Pharmacological Response.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：从构效关系到药理反应
Int J Mol Sci. 2025 Jul 19;26(14):6937. doi: 10.3390/ijms26146937.
2
Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores, Metabolic Parameters, and Laboratory Profiles in Type 2 Diabetes.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者心血管风险评分、代谢参数及实验室指标的影响
Life (Basel). 2025 Apr 29;15(5):722. doi: 10.3390/life15050722.
3
The Effects of SGLT2 Inhibitors on Blood Pressure and Other Cardiometabolic Risk Factors.

本文引用的文献

1
Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus: An open-label comparative study.维格列汀和瑞格列净作为 2 型糖尿病患者二甲双胍联合治疗的疗效和安全性：一项开放标签的比较研究。
Sultan Qaboos Univ Med J. 2024 May;24(2):243-249. doi: 10.18295/squmj.1.2024.006. Epub 2024 May 27.
2
High-density lipoprotein in diabetes: Structural and functional relevance.糖尿病中的高密度脂蛋白：结构与功能相关性。
J Diabetes Investig. 2024 Jul;15(7):805-816. doi: 10.1111/jdi.14172. Epub 2024 Feb 28.
3
Workplace Interventions for Type 2 Diabetes Mellitus Prevention-an Umbrella Review.
钠-葡萄糖协同转运蛋白 2 抑制剂对血压和其他心血管代谢风险因素的影响。
Int J Mol Sci. 2024 Nov 18;25(22):12384. doi: 10.3390/ijms252212384.
工作场所干预措施预防 2 型糖尿病：伞式综述。
Curr Diab Rep. 2023 Oct;23(10):293-304. doi: 10.1007/s11892-023-01521-3. Epub 2023 Sep 20.
4
Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.不同钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者中的安全性比较：一项随机对照试验的系统评价和网络荟萃分析。
Front Endocrinol (Lausanne). 2023 Aug 28;14:1238399. doi: 10.3389/fendo.2023.1238399. eCollection 2023.
5
Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents.2 型糖尿病靶点和治疗药物研究进展。
Int J Mol Sci. 2023 Aug 29;24(17):13381. doi: 10.3390/ijms241713381.
6
SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type.SGLT2 抑制剂增加总胆固醇、LDL 胆固醇、HDL 胆固醇并降低甘油三酯：60 项随机试验的荟萃分析，按剂量、种族和药物类型进行总体和分析。
Atherosclerosis. 2024 Jul;394:117236. doi: 10.1016/j.atherosclerosis.2023.117236. Epub 2023 Aug 9.
7
Metformin: update on mechanisms of action and repurposing potential.二甲双胍：作用机制及再利用潜力的最新研究进展。
Nat Rev Endocrinol. 2023 Aug;19(8):460-476. doi: 10.1038/s41574-023-00833-4. Epub 2023 May 2.
8
A Comparative Study of efficacy and safety of different Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitors in the Management of Patients with Type II Diabetes Mellitus.不同钠-葡萄糖协同转运蛋白 2（SGLT-2）抑制剂在 2 型糖尿病患者管理中的疗效和安全性的对比研究。
J Assoc Physicians India. 2022 Jun;70(6):11-12. doi: 10.5005/japi-11001-0001.
9
Efficacy and Safety of a Fixed Dose Combination of Remogliflozin Etabonate and Vildagliptin in Patients with Type-2 Diabetes Mellitus: A Randomized, Active-Controlled, Double-Blind, Phase III Study.瑞格列净恩格列净和维格列汀固定剂量复方制剂在 2 型糖尿病患者中的疗效和安全性：一项随机、阳性对照、双盲、III 期研究。
J Assoc Physicians India. 2022 Apr;70(4):11-12.
10
Efficacy and safety of novel sodium glucose cotransporter-2 inhibitor remogliflozin in the management of type 2 diabetes mellitus: A systematic review and meta-analysis.新型钠-葡萄糖共转运蛋白 2 抑制剂瑞格列净治疗 2 型糖尿病的疗效和安全性：系统评价和荟萃分析。
Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102315. doi: 10.1016/j.dsx.2021.102315. Epub 2021 Oct 22.